DAC raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-12-30. Anything still debated is marked as such rather than presented as settled.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Present on pituitary somatotroph cells |
| Signal pathway | Gs, cyclic AMP, protein kinase A | Sequence follows receptor activation |
| Main measured effect | Growth hormone release | Insulin-like growth factor 1 shifts indirectly |
| Half-life, binding form | Several days | Extended through serum albumin association |
| Half-life, unmodified form | About 30 minutes | Limited mainly by enzymatic cleavage |
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
Isolated cataplexy unto itself (i.e., in the absence of characteristically associated narcolepsy), admittedly a rare condition There is anecdotal and tentative, as-yet-undocumented information suggesting that clomipramine may address certain core features of hyperacusis, and possibly misophonia. In the case of hyperacusis, this appears to be especially the case at doses > 150 mg/d. As-with obsessive-compulsive disorder, a full response to any one dose may not be experienced for up to 12–16 weeks. Although lithium is most-associated with the treatment of bipolar disorder (where it is known for its general mood-stabilising features and to be especially useful in treating and preventing mania), it may have a certain place in the management of treatment-resistant depression (which is often of higher severity than other depressions which have not been addressed with ECT). In these cases it is often prescribed alongside SSRIs (e.g., fluoxetine, paroxetine), venlafaxine and various of the tricyclics (e.g., clomipramine, amitriptyline, nortriptyline, maprotiline), which is why it may feature sometimes in the discussion of depression being managed with clomipramine. Lithium also significantly reduces the long-term risk of suicide in general. In any case, it is not necessary to have a diagnosis of bipolar affective disorder (manic-depressive illness), or even to be considered to have subtle elements of it ("soft bipolarity"), to benefit from lithium in the context of treatment with clomipramine.
=== Drug-drug interactions === Drug−drug interactions (DDI) are one of the primary causes of adverse drug reactions which can result in serious health issues. In 1981, Aarons said that because of the practice at the time of multiple drug therapy, there was a good chance of drug-drug interaction. He reviewed the literature around pharmacokinetic interactions when there is a change of the disposition of the interacting drugs, in particular, the mechanisms that cause these changes. He noted that in drug-drug interactions both drugs are often affected, and it is necessary to develop "a model that describes the disposition of all interacting species." In 2011 Aaron was part of a team that critiqued the then two-fold method of assessing drug-drug interaction and proposed that there would be less bias if predictions were made using a wider range of data collected and the allowance of variability was included in the process. A research programme in 2017 that Aarons was involved in explored the mechanistic prediction of the oral bioavailability differences observed between the original formulation of a drug and that on its release. The study predicted that bioavailability of the original drug was due to reduced deactivation by an enzyme CYP3A4 in the intestine This was proven in the study, which concluded that "this work highlights the importance that formulations can have [when there are] clinically-relevant DDI involving CYP3A substrates...[and that]...
In September 2025, Eucalyptus introduced an AI chatbot prompting warning from professional bodies about the use of artificial intelligence in weight-loss programs. In late December 2025, peak eating disorder advocacy groups expressed concerns about the rapid rollout of GLP-1 weight-loss treatments alongside their aggressive marketing on social media. There were concerns from The Australia and New Zealand Academy for Eating Disorders that these marketing techniques could target people who do not need the medication. Juniper's Black Friday sale was one of the marketing practices in question.
== Life cycle == Blastocystis hominis has a multistage life cycle and is highly adaptable to a variety of host environments. The illness develops when the cyst form is consumed by contaminated food or water. When the cyst enters the colon, it grows into a vacuolar form, which is the key diagnostic stage usually seen in stool samples. The organism has two separate transmission patterns: external transmission and self-infection. During external transmission, thick-walled cysts discharged in feces can survive in the environment and stay infectious for long periods. These environmentally resistant cysts enhance transmission between hosts via the fecal-oral pathway. In autoinfection, thin-walled cysts form from the vacuolar form and excyst within the intestine, sustaining infection in the same host. The vacuolar shape can also transform into a multi-vacuolar. It may eventually transform into an amoeboid. The amoeboid stage, while less prevalent, is thought to play a role in pathogenicity. Binary fission is the principal mode of reproduction, occurring in both vacuolar and amoeboid forms. Under stress conditions, such as unfavorable environmental factors or host immunological responses, the organism can generate pre-cyst stages that eventually develop into mature cysts. This complicated life cycle, with its numerous physical forms, helps the organism colonize and spread to a wide range of host species.
Sources: en.wikipedia.org
The nervous system is the part of an animal that coordinates its actions by transmitting signals to and from different parts of its body. In vertebrates it consists of two main parts, the central nervous system (CNS) and the peripheral nervous system (PNS). The CNS consists of the brain and spinal cord. The PNS consists mainly of nerves, which are enclosed bundles of the long fibers or axons, that connect the CNS to all remaining body parts. Nerves that exit from the cranium are called cranial nerves while those exiting from the spinal cord are called spinal nerves.
=== Selection === The most common peptide aptamer selection system is the yeast two-hybrid system. Peptide aptamers can also be selected from combinatorial peptide libraries constructed by phage display and other surface display technologies such as mRNA display, ribosome display, bacterial display and yeast display. These experimental procedures are also known as biopanning. All the peptides panned from combinatorial peptide libraries have been stored in the MimoDB database.
=== Polonium === Polonium is produced in reactors from natural 209Bi, bombarded with neutrons, creating 210Bi, which then decays to 210Po via beta-minus decay. The final purification is done pyrochemically with sodium hydroxide at 500 °C. This is then followed by liquid-liquid extraction, with dibutyl Carbitol as the extractant.
Produced by Patrick Uden, directed by Taghi Amirani, made by Uden Associates 6 August New York! New York!, about sewage; New York makes enough sewage each day to fill the Yankee Stadium ten times, with seven million people; it had 80,000 miles of electric cable; a new sewage tunnel 60 miles long, 800 ft below ground, was being built, to be finished in the next century - the New York City Water Tunnel No. 3 is expected to be finished by 2032 13 August Fatal Attraction, about road transport; Britain subsidised rail £2 per mile, West Germany was £5 per mile; Reinhard Gutter of Cologne; traffic calming hadmainly begun in West Germany, from 1976; John Whitelegg; transport psychologist Carina van Knippenburg of the University of Gronigen; in 1987, the Dutch government introduced rationing of car transport, also trialled in Hong Kong; Ian Catling, and road pricing; Martin Paget in Birmingham; Talib Rothengatter, and the resignation of the Dutch government in April 1989; Philip Goodwin; Martin Mogridge of UCL. Narrated by Simon Ward, produced by Stewart Lansley, directed by Andy Mayer, made by Juniper Productions 20 August The Defender, building a new fighter plane in Canada; Chris Ball, of Bristol Aerospace in Winnipeg, and Bob Diemert are building a fighter plane in Carman, Manitoba; Bob Diemert flew one of his restored Hurricane XII aircraft in the 1969 Battle of Britain; the Commemorative Air Force at Harlingen, Texas; his plane attempts to take off, but it is something akin to a scene from Those Magnificent Men in Their Flying Machines.
The role of FICD in BiP AMPylation (and de-AMPylation) on Thr518 is well supported by biochemical and structural studies. Evidence has also been presented that in some circumstances FICD may AMPylate a different residue, Thr366 in BiP's nucleotide binding domain.
Sources: en.wikipedia.org
=== 2018–present === On January 9, 2018, construction workers broke ground on a new 5,100 square foot (470 m2) wound healing center at the hospital, it would be double the size of the old facility. The wound healing center was completed at the end of 2018 and included six treatment rooms, three hyperbaric chambers, waiting area and a lobby. On May 22, 2019, AdventHealth signed a definitive agreement to purchase Lake Wales Medical Center from Community Health Systems. On September 1, AdventHealth took over the management of Lake Wales Medical Center, it had purchased the hospital for $10,146,000 and renamed it AdventHealth Lake Wales. On January 1, 2021, all hospitals were required to have their chargemaster on its website by the Centers for Medicare & Medicaid Services. In early February, 2023, almost all of the AdventHealth hospitals had their chargemaster on their website, including AdventHealth Lake Wales.
The public inquiry into the 2017 Manchester Arena bombing finds that MI5 missed a significant chance to take action that might have stopped the attack when they failed to obtain intelligence that would have led them to follow Salman Abedi to the car where he was storing explosives. Ken McCallum, the director-general of MI5, says he regrets that the intelligence was missed. 3 March COVID-19 in the UK: Lockdown Files: The latest leaked WhatsApp messages published by the Daily Telegraph are reported as appearing to show former Health Secretary Matt Hancock and Cabinet Secretary Simon Case joking about locking people in quarantine hotels. Office for National Statistics data for the week up to 21 February indicates that COVID-19 infections were increasing in England and Wales, but decreasing in Northern Ireland, while the situation in Scotland was uncertain. In England, the number of people testing positive for COVID-19 was estimated to be 1,298,600 (roughly 2.31% of the population around 1 in 45). The Commons Select Committee of Privileges finds that former prime minister Boris Johnson may have misled Parliament over the Partygate scandal after evidence suggested breaches of COVID-19 rules would have been "obvious" to him. In response Johnson says that none of the evidence shows he "knowingly" misled parliament, and that "it is clear from this report that I have not committed any contempt of parliament". Buckingham Palace announces the first state visit to be made by Charles III and Camilla as King and Queen Consort; they will travel to France and Germany from 26 to 31 March.
eV, higher than what is predicted in theory for continuum plates of the same thickness, due to nonlocal microstructural constraints such as nonlocal coupling of particle rotational degrees of freedom. On the other hand, resistance to bending is found to be greatly reduced in nanoparticle monolayers that are supported at the air/water interface, possibly due to screening of ligand interactions in a wet environment.
=== Improving cell survival === Among the approaches aimed at improving cell survival in the presence of mutant huntingtin are correction of transcriptional regulation using histone deacetylase inhibitors, modulating aggregation of huntingtin, improving metabolism and mitochondrial function and restoring function of synapses.
Emdogain which has been shown to significantly improve probing attachment levels (1.1mm) and periodontal pocket depth reduction (0.9mm) when compared to a placebo or control materials. Resorption rates ranging from six to 24 weeks depending on its different chemical structures. With the resorbable membrane used, the membrane will bio-degrade. There is no need for a second surgery to remove the membrane, this will prevent any disruption to the healing process of the regenerated tissues. A synthetic resorbable membrane (eg: Powerbone Barrier Membrane) is an ideal alternative to the resorbable collagen material. Randomised clinical trials compared the stability of augmented bone between a synthetic resorbable membrane and a collagen membrane with guided bone regeneration simultaneous to dental implant placement in the aesthetic zone in terms of facial bone thickness. Success depends on several factors: osteoblasts being present at the site, a sufficient blood supply, stabilisation of the graft during healing, and soft tissue not being under tension.
Sources: en.wikipedia.org
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.
It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.
Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.